Previous 10 | Next 10 |
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
TORRANCE, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease (SCD) treatment, announced today several steps it has taken in response to the Coronavirus (COVID-19) pandemic. Within the overall SCD community, Emmaus is workin...
TORRANCE, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB:EMMA), a leader in sickle cell disease treatment, today announced that Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer, and Jay Sherwood, Chief Financial Officer, will presen...
-- Company Reports Highest Gross Monthly Sales of 2019 and Total Gross Sales of $7.8 Million in the Fourth Quarter -- TORRANCE, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease (SCD) treatment, today reported pr...
TORRANCE, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, announced today the top-line preliminary results in the first patient in the company’s Pilot/Phase 1 study in the treatment of diverticulosis. Th...
Quick Take Beam Therapeutics ( BEAM ) intends to raise $100 million from the sale of its common stock, per an amended registration statement . The company is advancing a pre-clinical set of programs for the treatment of various diseases that may possibly be treated via gene editing of a s...
TORRANCE, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, responded today to the draft evidence report by ICER dated January 23, 2020 examining the effectiveness and value of Crizanlizumab, Voxelotor, and L-glu...
TORRANCE, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, is pleased to announce a new adherence program available to sickle cell disease (SCD) patients in collaboration with US Bioservices, an AmerisourceBerge...
TORRANCE, Calif., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, today reported that it received the initial purchase order relating to taiba Healthcare’s early access program for Endari® (L-glutamine oral...
TORRANCE, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, today reported that it expects to receive shortly the initial purchase orders relating to taiba Healthcare’s early access program for Endari®...
News, Short Squeeze, Breakout and More Instantly...
Emmaus Life Sciences Incorporation Company Name:
EMMA Stock Symbol:
NYSE Market:
Emmaus Life Sciences Incorporation Website:
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program PR Newswire TORRANCE, Calif. , July 12, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a commercial-stage biopharmaceuti...
Emmaus Life Sciences Reports 2023 Financial Results PR Newswire TORRANCE, Calif. , July 3, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today r...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...